What is the Sorafenib tosylate?

Sorafenib tosylate is White to off-white crystalline powder, while it's Molecular Formula is C21H16ClF3N4O3. White to off-white crystalline powder An inhibitor of Flk-1 (VEGFR), PDGFR and Raf kinases.

What is the CAS number for Sorafenib tosylate?

The CAS number of Sorafenib tosylate is 475207-59-1.

What is Sorafenib tosylate (475207-59-1) used for?

Sorafenib (475207-59-1) was initially developed as a Raf kinase inhibitor, IC50 = 6 nM, but has been shown to inhibit many receptor tyrosine kinases including BRAF (IC50 = 22 nM); VEGFR-2 (IC50 = 90 nM); VEGFR-3 (IC50 = 20 nM); PDGFR-β (IC50 = 57 nM); Flt3 (IC50 = 58 nM); c-KIT (IC50 = 68 nM); FGFR-1 (IC50 = 580 nM).1?Paradoxically more potent in a cellular assay (IC50 = 20 nM) compared to an isolated enzyme assay (IC50 = 107 nM) for c-Fms.2?Inhibits activation of MAPK pathway and ERK phosphorylation.3?Induces caspase-independent apoptosis in melanoma cells.4?Sorafenib is a clinically useful anticancer agent.

What is the Sorafenib tosylate?

Sorafenib tosylate is White to off-white crystalline powder, while it's Molecular Formula is C21H16ClF3N4O3. White to off-white crystalline powder An inhibitor of Flk-1 (VEGFR), PDGFR and Raf kinases.

What is the CAS number for Sorafenib tosylate?

The CAS number of Sorafenib tosylate is 475207-59-1.

What is Sorafenib tosylate (475207-59-1) used for?

Sorafenib (475207-59-1) was initially developed as a Raf kinase inhibitor, IC50 = 6 nM, but has been shown to inhibit many receptor tyrosine kinases including BRAF (IC50 = 22 nM); VEGFR-2 (IC50 = 90 nM); VEGFR-3 (IC50 = 20 nM); PDGFR-β (IC50 = 57 nM); Flt3 (IC50 = 58 nM); c-KIT (IC50 = 68 nM); FGFR-1 (IC50 = 580 nM).1?Paradoxically more potent in a cellular assay (IC50 = 20 nM) compared to an isolated enzyme assay (IC50 = 107 nM) for c-Fms.2?Inhibits activation of MAPK pathway and ERK phosphorylation.3?Induces caspase-independent apoptosis in melanoma cells.4?Sorafenib is a clinically useful anticancer agent.

Product Class

475207-59-1

Product Name：Sorafenib Tosylate
Molecular Formula：C₂₁H₁₆ClF₃N₄O₃
Purity：99%
Molecular Weight：637.03

Inquiry

Product Details:

CasNo： 475207-59-1

Molecular Formula： C₂₁H₁₆ClF₃N₄O₃

Appearance： White to off-white crystalline powder

Buy Reliable Quality Sorafenib Tosylate,Sale 475207-59-1 Lowest Price

Molecular Formula:C21H16ClF3N4O3
Molecular Weight:637.03
Appearance/Colour:White to off-white crystalline powder
Boiling Point:523.3 °C at 760 mmHg
Flash Point:270.3 °C
PSA：155.10000
Density:1.454 g/cm³
LogP:8.40910

Sorafenib Tosylate(Cas 475207-59-1) Usage

Sorafenib tosylate is an organosulfonate salt, consisting of sorafenib. This compound is a synthetic agent designed to target growth signaling and angiogenesis. Functioning as a multi-targeted kinase inhibitor, Sorafenib tosylate interferes with cancer cell growth by blocking proteins that signal cell division and inhibiting the formation of new blood vessels crucial for tumor growth. Unlike chemotherapy drugs, Sorafenib is not classified as such. Instead, it operates by disrupting specific cellular processes involved in cancer development, ultimately impeding tumor growth and potentially causing cancer cell death.

475207-59-1 Relevant articles

STUDY ON THE SCALEABLE SYNTHESIS OF SORAFENIB TOSYLATE FOR TREATMENT OF CANCER

MD Le, ND Vu, THA Pham, HT Cao

, Journal of Science and Technique, VOL. 13 NO. 03 (2018)

The objective of this paper is to study synthesis of sorafenib tosylate in large scale up to 220 gram. In this process, all intermediates, as well as final product, were recrystallized as purification method without chromatography, and it ample useful to reduce cost of commercial treatment cancer drug.

A Patient with Advanced Hepatocellular Carcinoma Treated with Sorafenib Tosylate Showed Massive Tumor Lysis with Avoidance of Tumor Lysis syndrome

Satoru Joshita, Kaname Yoshizawa, Kenji Sano, Satoshi Kobayashi, Tomohiro Sekiguchi, Susumu Morita, Atsushi Kamijo, Michiharu Komatsu, Takeji Umemura, Tetsuya Ichijo, Akihiro Matsumoto, Eiji Tanaka

, Internal Medicine, VOL 49 (2010)

Oral administration of sorafenib at 800 mg/day with careful observation was commenced in 2009. Laboratory investigations on day 7 showed massive tumor lysis. An abdominal CT showed multiple low density areas and tumor markers decreased, indicating extended tumor necrosis.

Relevant Products

Milvexian
CAS：1802425-99-5
Epirubicin Hcl
CAS：56390-09-1
Labetalol hydrochloride
CAS：32780-64-6